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End product hydroimidazolone is associated with retinopathy in type 1 diabetes 
patients” should read: ”Serum levels of the Advanced Glycation End product 
hydroimidazolone are associated with retinopathy in type 1 diabetes patients”. 
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 Page 7 within 5.2: "Organs mainly affected are the eyes, kidneys and nerves (15); 
diabetic retinopathy." should read: "Organs mainly affected are the eyes, kidneys and 
nerves (15) with diabetic retinopathy, nephropathy and neuropathy, respectively." 
 Page 28: "(Blood tests were collected after overnight fasting." Omit initial parenthesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                       To my patients 
 
 
 
 
 
 
 
 
 2
Contents 
 1. Preface  
 2. Acknowledgements 
 3. Abbreviations 
 4. List of papers  
 5. Introduction 
 5.1 Diabetes  
 5.2 Hyperglycemia and vascular complications of diabetes 
 5.3 Diabetic retinopathy; background 
 Pathogenesis 
 Risk 
 Clinical aspects 
 Classification 
 Biochemical mechanisms  
 ROS and Oxidative stress 
 5.5 Advanced Glycation Endproducts (AGEs):  
            Background, pathologic relevance and detection  
 AGEs; definition and examples 
 Methylglyoxal derived AGEs 
 AGEs and disease 
 Circulating AGEs; AGE/RAGE interaction 
 Inhibition of AGE 
 AGEs, VEGF and the eye 
 AGEs; different methods for detection 
 6. Aims of research 
 7. Subjects and methods 
 7.1 Subjects 
 7.2 Methods 
 8. Summary of main results  
 9. Discussion 
       9.1 Methods 
             Clinical and Photographic methods of retinopathy diagnosis 
             Immunoassay method 
       9.2 Results 
 10. Concluding remarks 
 11. References 
 
Papers I - IV 
 
 
 3
1. Preface “There is only one thing about which I am certain, and that is that there is very 
little about which one can be certain.” W. Somerset Maugham 
 
2. Acknowledgements 
This piece of work was carried out during intervals between 2000 and 2007 at the Diabetes 
Research Centre of Aker and Ullevål University Hospitals, Oslo, with the facilities of Aker 
University Hospital and the Hormone Laboratory, Oslo. Financial support has been granted 
by the Norwegian Foundation for Health and Rehabilitation after recommendations from the 
Norwegian Diabetes Association; the Research Forum of Ullevål University Hospital (FUS) 
and the Research Forum of Aker University Hospital (FAS); the Diabetes Research Centre of 
Aker and Ullevål University Hospitals, the Regional Health Board (Helse Øst), my own 
pocket and the Remembrance Foundation of Inger Holm. 
 
First and foremost, I would like to thank the core of the Diabetes Research Centre, in this 
context meaning my supervisor, Professor Kristian F. Hanssen for his support and stimulation 
through his immense knowledge and optimism, and secretary Beth Thyrdal for reiterating 
positive feed-back. I am also grateful to the former professor at the Ophthalmological 
Department at Ullevål University Hospital, Dr. Olaf Brinchmann-Hansen, who triggered me 
into getting seriously involved in diabetes research. I would like to thank my Swedish co-
authors, Professor Elisabet Agardh and Professor Carl-David Agardh for having faith in me as 
a novice; for their professional attitude and sharing of knowledge. I owe greatful thoughts to 
professor Kåre Birkeland for including me as scientist and to Professor Egil Haug of the 
Hormone Laboratory for providing me with excellent facilities and the following co-workers; 
Peter Torjesen, Jens Petter Berg, Terje Lund and Aase-Brith Jensen, whose contributions have 
been inspiring for my clinical mind. Furthermore, at the Hormone laboratory; Turi Arnesen 
Siegwarth for initially letting me work on AGE immunoassays and Bård Rasmussen for PC 
support, the remaining “white coats” for including me as member of staff. Thanks of 
appreciation go to Bente K. Kilhovd and Tore J. Berg for letting me continue working with 
their assays and for fruitful discussions. I want to thank the first-author Torild Skrivarhaug in 
particular, and the other colleagues and co-authors at the Pediatric Department of Ullevål 
University Hospital, Geir Joner and Hans-Jacob Bangstad for inclusive discussions. In 
addition to contribution from Ragnheiur Bragadóttir and Ingar Stene-Johansen and their 
surgical assistance, I owe thanks to the friends and colleagues at the Ophthalmological 
Department of Ullevål University Hospital; to Sonja Lerdal for her enthusiasm, and former 
and current head of the Ophthalmological Department, Kristin Eidal and Ketil O. Eriksen for 
not forgetting about me during my time as a “sub-clinician”. I thank Lars Christian Stene at 
the Norwegian Institute of Public Health for inspiring discussions and Leiv Sandvik at the 
Centre for Clinical Research at Ullevål University Hospital for his positive attitude and 
original thoughts; often - through extracurricular agendas - contributing beyond what is 
expected. Thank you, librarians at Ullevål and Aker University hospitals!  
Thank you, friends and colleagues at the Institute of Aviation Medicine for support, high 
spirit and for keeping me grounded (!). For teaching endurance; Thank you, friends at the 
rowing club for contagious mental strength and laughter, and for having given me fantastic 
experiences of achieving common goals backwards. Thanks to my stand-by American friends: 
Hy & Rena and the Songy family. Thanks to my father Terje, my mother Annemone and my 
brother Per for their mere being. A humble “Thank you all” to my family Kristin, Sigurd, Jon 
and Eivind for continuously letting me feel important on other arenas.  
 
To the ones not mentioned; thank you for the open doors. 
________________________________________________________________________ 
 4
 
3. Abbreviations 
21 21 trans-membrane cell-linker 
ADRB3 3 adrenergic receptor gene 
AGE(s) advanced glycation end product(s) 
ALR aldose reductase 
ALT-711 alagebrium chloride 
AMD age-related macular degeneration 
BRB blood-retinal barrier 
BSA bovine serum albumin 
CEC carboxyethylcysteine 
CEL carboxyethyllysine 
CI confidence interval 
CMC carboxymethylcysteine 
CML carboxymethyllysine 
CSME clinically significant macular edema 
DAG diacylglycerol 
DCCT diabetes control and complications study 
DELFIA dissociation enhanced lanthanide fluoro-immunoassay 
DNA deoxyribonucleic acid 
DNR diabetes and no retinopathy 
DOLD 3-Deoxyglucosone-derived lysine dimer 
DR diabetic retinopathy 
ELISA enzyme-linked immunosorbent assay 
ETDRS early treatment of diabetic retinopathy study 
GOLD glyoxal imidazolium crosslink 
HbA1c hemoglobin A1c 
HFE HLA-H antigen 
HPLC high performance liquid chromatography 
iBRB inner blood-retinal barrier 
ICAM-1 intercellular adhesion molecule 
KHL keyhole limpet hemocyanin  
LC-MS  liquid chromatography mass spectrometry 
LMW low–molecular weight  
ME macular edema 
MG methylglyoxal 
MG-BSA  methylglyoxal-modified bovine serum albumin 
MG-H1  methylglyoxal hydroimidazolone isomer 1 
MOLD methylglyoxal imidazolium crosslink 
MS mass spectrometry 
MSMS tandem mass spectrometry 
NADPH reduced form of Nicotinamide adenine dinucleotide phosphate  
NO nitric oxide 
NPDR non-proliferative diabetic retinopathy 
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NVD neovascularization of the optic disc 
NVE neovascularization elsewhere (than of the optic disc) 
oBRB outer blood-retinal barrier 
OR odds ratio 
PAI-1 plasminogen activator inhibitor-1 
PDR proliferative diabetic retinopathy 
PKC protein kinase C 
PTB N-phenacylthiazolium bromide 
RAGE receptor for AGE 
ROS reactive oxygen species 
RPE retinal pigment epithelium 
RR relative risk 
SD standard deviation 
sRAGE endogenous secretory RAGE 
TGF-1  transforming growth factor- 1 
UDP-GlcNAc N-acetyl glucosamine  
UKPDS United Kingdom Prospective Diabetes Study 
VCAM-1 endothelial vascular cell adhesion molecule 1 
VEGF vascular endothelial growth factor 
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5. Introduction:  
5.1 Diabetes  
Diabetes mellitus is a heterogeneous group of diseases characterized by high glucose levels in 
the blood and urine. The earliest known mentioning of the word “diabetes” dates back to a roll 
of papyrus from the 3rd Egyptian dynasty and the physician Hesy-Ra. “Diabetes” means 
“going through”, referring to the polyuria which is one of the symptoms in diabetes. The Latin 
word “mellitus” means “honey-sweet”, referring to the sweet taste of the urine from a diabetic 
subject (1).  
The two main forms are type 1- and type 2-diabetes mellitus.  
The signs and symptoms of diabetes mellitus are caused by lack of insulin or inability to 
respond to insulin, or both. Type 1-diabetes is characterized by autoimmune destruction of the 
pancreatic beta cells, causing insulin deficiency. Type 2-diabetes is due to a relative insulin 
deficit, its pathogenic mechanisms combining resistance to insulin with a relative defect of 
insulin secretion. There are huge variations in incidence rates of diabetes mellitus type 1- 
between different geographical areas and ethnical groups, the Scandinavian countries ranging 
among the highest (2). The prevalence of both type 1- and type 2-diabetes seems to increase 
worldwide, Norway included (3). Studies linking WHO’s global database with demographic 
estimates of the UN calculate a drastic increase in the prevalence of diabetes mellitus on a 
world basis within the next 20 years, estimating the number of adults with diabetes in the 
world rising (from 135 million in 1995) to 300 million in the year 2025 (3). In Norway today, 
90,000 – 120,000 people have been diagnosed with diabetes, but it is estimated that there are 
almost as many undiagnosed cases (4). How to face this epidemic challenge of diabetes is an 
up-to-date political issue (5). Additional challenges as diabetes increases not only include how 
to deal with the disease itself, but how to deal with its vascular complications; especially since 
preventive measures produce better individual health and far less health expenses (6) (7). As 
of yet, there are no Norwegian figures available, but the cost of treatment of diabetes and its 
complications in Sweden amounts to 8% of its direct healthcare expenses (8). Type 2-diabetes 
among persons at risk of developing the disease can be primarily prevented or postponed 
through life-style intervening measures (9). 
 
5.2 Hyperglycemia and vascular complications of diabetes 
Diabetes leads to disease in both large and small vessels (macro- and microvascular 
complications).  
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Macrovascular complications are due to atherosclerosis and can occur in large blood vessels 
in any part of the body, affecting the brain, heart, and peripheral arteries (e.g of the lower 
extremities) giving rise to stroke, cardiac heart disease and peripheral arterial disease. The risk 
for - and burden of - macrovascular mortality and morbidity are increasing (10) (11), in 
particular when microvascular disease already exists (12) (13) (14).  
Microvascular complications are due to progressive pathology of the small arterioles. Organs 
mainly affected are the eyes, kidneys and nerves (15); diabetic retinopathy. Diabetic 
retinopathy is the most important cause of permanent visual impairment and/or secondary 
blindness in the working-age population in the Western world (16) (17). The findings from 
the small, but early Oslo and Stockholm studies were confirmed in the DCCT, stating that 
decreasing blood glucose levels by intensive insulin treatment could prevent or delay the 
development of diabetic microvascular complications (18) (19) (20) (21). This was later also 
confirmed in type 2-diabetes in the UKPDS (22). However, with time the vast majority of all 
patients with diabetes develops background retinopathy, as many as 40–50% observed 
progressing to proliferative retinopathy within 25 years of diabetes onset (23). Over the last 
decades, proliferative retinopathy is declining in many centres (24) (25) (26).  
Susceptibility to diabetic microvascular complications reveals a great interindividual variation 
(27). Not all patients with diabetes develop complications, but multiple vascular 
complications occur in almost 20 % of patients (28). It has also been speculated whether there 
may be a chronological order in which microvascular complications develop (29) (30). In 
longitudinal studies, diabetic patients with retinopathy at baseline are at increased risk of 
developing diabetes-associated peripheral neuropathy (31) and coronary heart disease (32).  
In type 1-diabetes, almost all patients develop signs of retinopathy in the first 20 years.  
In type 2-diabetes, up to a third of patients have retinopathy at the time of diagnosis (33), 
increasing to two-thirds within 20 years. However; as the incidence and prevalence of both 
type 1- and type 2-diabetes are increasing, on a population level complications are expected to 
increase. It is thus important for the prevention of diabetic retinopathy and its progression that 
organized measures are implemented. However, in order to identify treatable retinopathy and 
apply further prophylactic measures, joint medical efforts are warranted. Inevitable and silent 
progression of diabetic retinopathy may otherwise be overlooked until the patients experience 
vision loss. In general, current recommendations apply for retinopathy screening to be 
undertaken annually.  
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5.3 Diabetic retinopathy; background. 
 
Diabetic retinopathy was first recognized after the invention of the direct ophthalmoscope in 
the middle of the 19th century (34). In 1856, Eduard Jäger observed and described diabetic 
macular changes (35), his findings and interpretations meeting skepticism from the 
establishment of ophthalmology. Histopathological proof came in 1872 with Nettleship’s 
publication (36). The proliferative changes of diabetic retinopathy, including vitreous 
hemorrhages and retinal detachment due to traction, were described in 1876 by Wilhelm 
Mantz (37). With the discovery of insulin in 1921 by Banting and Best (38) the treatment of 
diabetes was revolutionized. The expected “final cure” for diabetes appeared too optimistic, 
though, before the growing awareness of the association between diabetes and its 
complications. In insulin treated survivors, the prevalence of diabetic complications increased 
dramatically, too, further challenging the patients, clinicians and researchers. Dr. Elliot P. 
Joslin (already in 1931, only 10 years after the discovery of insulin) concisely described his 
clinical observations: “With the advent of insulin, we moved from the era of diabetic coma to 
the era of diabetic complications” (39). Ballantyne described in 1943 diabetic retinopathy as a 
unique vasculopathy rather than caused by hypertension and atherosclerosis (40). Finally, in 
1954, the work of Knud Lundbæk created acceptance for the concept of diabetic 
microvasculopathy as a diabetic entity (41).  
In the following second half of the 20th century, experimental treatment modalities evolved 
with the changing needs of the diabetic patient. Meyer-Schwickerath pioneered 
photocoagulation. His principles of using light on retinal conditions (initially reflected 
sunlight, and later light from a xenon arc) were applied and improved by several others 
(Morón-Salas, Wetzig, Amalric, Okun, Wessing et al) (42). Laser treatment eventually turned 
out the most successful means of photocoagulation (43) (44), still used world-wide. Several 
surgical approaches for treating diabetic retinopathy were also developed, even experimental 
procedures such as pituitary ablation (45). In 1968, The Airlie House Symposium gathered 
devoted ophthalmologists and diabetologists to define the future course for research and 
development in the field of diabetic retinopathy. Systematic approaches to the growing 
challenges of diabetic retinopathy continue to produce valuable insight. Basic epidemiological 
studies on both type 1 and type 2 diabetes have shown beneficial effects of glycemic control 
on onset and progression of diabetes retinopathy (21) (22).  
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Pathogenesis  
Diabetic retinopathy is caused by deranged systemic and local (retinal) metabolism, 
potentially capable of destroying the architecture and specialized function of this vascularized 
neural tissue of the eye. Alterations in and between the functional and supportive cells of the 
retina occur before ophthalmoscopical signs of retinopathy become clinically evident. As 
vascular and neural cell defects seem to depend on one another, one might question at what 
point diabetic retinopathy actually starts. Electroretinographically observed alterations of 
retinal nerve cell function may occur quite early in the course of retinopathy (46), and 
neuroretinal dysfunction in general (measured by ERG, dark adaptation, contrast sensitivity, 
colour vision) has in fact been shown even before vascular lesions are seen on the fluorescein 
angiogram (47). In addition, symptoms such as vision changes can be transitory or occur late, 
hence an insufficient parameter for both severity grading and visual prognosis.  
Apoptosis of the contractile pericytes that embrace the microvessels denotes a primal 
anatomical change, hereby facilitating later microaneurysm development (48) (See Fig. 1).  
 
Fig. 1 Early capillary targets (effects) in the development of diabetic retinopathy 
          The endothelium                                                          The pericytes                
           (aneurysm formation)                                                  (apoptosis)                                                             
                
                                                                   
Schematic diagram of pathogenesis of diabetic retinopathy  
             (From Kohner, EM et al 1995, Diabetes) 
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In the earliest, preclinical stages of diabetic retinopathy, the retinal blood flow increases. 
Leukocytes and monocytes later adhere to the vessel walls, and localized hypoxia results from 
capillary closure (49) (50) (51). Further autoregulatory and hemodynamic dysfunction cause 
the retinal veins to dilate, eventually appearing bead-like. Cellular and intercellular barrier 
derangement may cause intraretinal hemorrhages and leakage of plasma and precipitation of 
its lipid and protein constituents (48). Of all tissues, retina has the highest rate of oxygen 
consumption (52). When poor perfusion (revealed by fluorescein angiography) and 
microinfarctions of the retinal neurons occur (denoted by soft exudates), ischemia may 
include larger retinal areas. Further progression may trigger neovascularization, initiated by 
sprouting of new (but leaky!) retinal vessels due to stimulation by growth factors. These 
factors may leak from the systemic circulation or be of intraocular origin. VEGF is considered 
the most important, whereas examples of others are insulinlike growth factor 1, hepatocyte 
growth factor and basic fibroblast growth factor (53) (54) (55). At this stage, the clinical 
condition of PDR is reached, and panretinal laser treatment will decrease the stimuli for 
further worsening.  
Macular edema is caused by increased vascular permeability in the macular area. Generalized 
macular edema is probably due to a widespread blood-retinal barrier (BRB) breakdown, 
secondary to glucose-induced microvascular damage. Anatomically, there are actually two 
blood-retinal barriers that may break due to ocular disease: The outer BRB consists of the 
retinal pigment epithelium, regulating trans-epithelial diffusion by the intercellular tight 
junctions, further separating the choroidal circulation from the retina. The inner BRB consists 
of tight junctions of the endothelial cells of retinal vessels and provides a selective mechanism 
for the retina to regulate its environment during varying metabolic demands. It is most fragile 
in diabetic retinopathy; “retinal disease of diabetes mellitus”. 
Diabetic retinitis, the old descriptive term of proposed inflammatory changes of the retinae in 
diabetic patients, may in part be justified etymologically: Compared with patients with less 
severe retinopathy, patients with severe NPDR or worse have elevated serum levels of 
chemokines, supporting the hypothesis that inflammation is involved in the pathogenesis of 
retinopathy (56).  
 
Risk  
The longer the duration of diabetes, the greater the risk of diabetic retinopathy (57) (58). The 
chronic hyperglycemia or total glycemic load associated with diabetes over time is thought to 
be the primary cause of diabetic retinopathy (DR) (See Fig 2.) (21).  
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One of the most important treatable risk factor besides hyperglycemia is hypertension; both in 
patients with diabetes type 1 (59) (60) and type 2 (61).  
Indirectly, underlying genetic predispositions for the background disease (diabetes mellitus) 
may be of etiological importance for its complications, too. Especially in diabetic 
nephropathy, direct genetic associations have been revealed (62), already suggested by its 
much lower incidence over time compared to retinopathy. Among the most intriguing 
candidate genes in diabetic retinopathy involve the expression of VEGF (vascular endothelial 
growth factor), ALR (rate limiting enzyme of the polyol pathway), RAGE (receptor for 
AGE), ICAM-1 (intercellular adhesion molecule), ADRB3 (3 adrenergic receptor gene), 
HFE (or HLA-H antigen), and 21 integrin (specific trans-membrane cell-linker)(63). 
Evidence suggests that familial factors strongly influence the susceptibility to complications, 
especially regarding nephropathy (64) (65) (66). Recent studies report of female 
preponderance for diabetic complications (67) and genome-wide linkage analysis linking 
chromosome 1p to diabetic retinopathy (68).  
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An association between nephropathy and retinopathy has clinically been shown, and a 
previous study (29) demonstrated that diabetic nephropathy is strongly associated with 
diabetic retinopathy. Other recent studies have confirmed the presence of diabetic retinopathy 
itself revealing patients at risk of diabetic nephropathy (69); in type 1 diabetics maybe even 
more so (70). Squandrito and Cucinotta (1991) reported that the severity of diabetic 
nephropathy in type 1- and type 2-diabetes increases the prevalence of diabetic retinopathy 
(71). However, both complications have hyperglycemia in common, making it difficult to 
dissect the relationship. 
Unfavourable lipid profiles have been associated with the development and progression of 
diabetic retinopathy (72), and a new study suggests that lowering lipids by fenofibrate reduces 
the need for laser treatment (73). 
 
Clinical aspects  
Preserving vision is, however, the most important treatment goal for both patient and 
ophthalmologist, being far simpler and more successful a task in the early stages of 
retinopathy development, and – even better; before its evolvement, when preventive measures 
may be applied more efficiently. Additional helpful management strategies as DR progresses 
to macular edema (ME/CSME) and/or PDR include retinal laser therapy, albeit often at the 
expense of functioning retina (74). With retinal traction and/or non-resorbing vitreous 
hemorrhage, vitreoretinal surgery may become necessary.  
 
Classification  
Diabetic retinopathy is classified according to stage and treatment indications, also revealing 
its potential vision threat (75). The terms no retinopathy (DNR), non-proliferative retinopathy 
(NPDR) and proliferative retinopathy (PDR) of diabetes reflect the chronological 
development of this complication left untreated/suboptimally treated; with or without macular 
edema (ME) or clinically significant macular edema (CSME). As mentioned, these latter 
entities may coexist with DR. Although uncommon, they may be solely present.  
 
Biochemical mechanisms and ROS  
A definite biochemical explanation of diabetic retinopathy has not been established, but 
interaction of various pathways is obvious. Four main candidate mechanisms for the 
deleterious effect of hyperglycemia are the following (76) (See Fig. 3):  
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I     Polyol/Aldose reductase pathway  
II   Hexosamine pathway  
III  Protein kinase C pathway with activation of vascular endothelial growth factor  
IV  Advanced Glycation End products pathway (77).  
 
I  Increased glucose flux through the polyol or aldose reductase pathway will lead to sorbitol; 
a reaction catalyzed by the enzyme aldose reductase. The depletion of cellular cofactor 
NADPH may decrease NO production in endothelial cells, altering the redox balance of the 
cell. NADPH is also an essential cofactor for regeneration of the important intracellular 
antioxidant, reduced glutathione, hereby increasing the susceptibility to intracellular oxidative 
stress. Increased intracellular sorbitol may reduce levels of myo-inositol, which in animal 
studies is associated with the development of neuropathy, nephropathy and retinopathy (78). 
 
II  Increased hexosamine pathway activity: Some of the fructose-6-phosphate (Fructose-6-P) 
from glycolysis is diverted via N-acetyl glucosamine (UDP-GlcNAc), changing gene 
expression of transcription factors by modification of serine and threonine residues. 
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(79) (e.g. increased modification of transcription factor Sp1 increases expression of TGF-1 
and PAI-1, promoting blood vessel pathology.) 
 
III  Increased protein kinase C pathway activity: Hyperglycemia increases intracellular 
content of glyceraldehyde-3-phosphate, which stimulates synthesis of diacylglycerol (DAG); 
further activating protein kinase C (PKC). Activation of the -isoforms of PKC in the vessels 
of nerves, kidneys and retinae of diabetic animals may produce vascular damage including 
increased permeability, altered blood flow, NO dysregulation and leukocyte adhesion. 
  
IV  Increased production of AGE and its precursors appear to cause cellular dysfunction via 
three routes (see also Fig 5):  
1. By modification of intracellular protein; regulatory proteins of gene transcription among 
the most important. 
2. By modification of intercellular signaling between cell and matrix after diffusion of AGE 
precursors out of the cell. 
3. By modification of extracellular proteins of the bloodstream (e.g. albumin), enabling 
AGE-receptors interaction and activation. This in turn causes vascular pathology from 
production of inflammatory cytokines and growth factors. 
 
ROS and oxidative stress 
Reactive oxygen species (ROS) are highly reactive molecules in biological systems, 
potentially harmful when insufficiently removed. Oxidative stress is the result of a relative 
imbalance of ROS and antioxidative status and may interfere with pathways I – IV. 
Generation of ROS occurs when oxygen is converted to the free radical O2¯ (superoxide), 
which then is dismutated to H2O2 by the enzyme superoxide dismutase. H2O2 may be 
enzymatically converted to H2O by catalase or glutathione peroxidase, or to HO by reaction 
with copper or iron (80).  
ROS have various sources, including normal oxidative phosphorylation in the mitochondria; 
and various effects, including cell membrane dysfunction. If DNA is altered, the expression of 
a range of signaling or enzymatic proteins may also be altered, via modified transcription 
factors. Oxidative stress is central in diabetic complications, and there is most probably an 
interaction between ROS and AGEs (81) (76). AGEs – directly or indirectly – stimulate ROS 
production (82) and studies have shown a decreased formation of AGEs due to antioxidant 
effect (83). In diabetes, the formation of ROS/AGE may be a self-perpetuating cycle (84). 
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Potential sources of ROS in the Maillard reaction are many; auto-oxidation of glucose; Schiff 
bases; Amadori adducts and AGEs (85). (See Fig. 3 and Fig. 4)  
 
5.5 AGEs (Advanced Glycation End products):  
      Background, pathologic relevance and detection 
 
  
MAILLARD, Louis Camille (1878-1936). 
AGEs will now be described in more detail, as this is a central topic in the present 
dissertation. 
The basis for formation of AGEs – the Maillard reaction – takes place when reducing sugars 
react non-enzymatically with amino acids on proteins forming Advanced Glycation End 
products; AGEs (See Fig. 4A). It was first described in Louis Camille Maillard’s scientific 
paper of 1912; “Action des acides aminés sur les sucres: formation des mélanoidines par voie 
méthodique” (86).  
 
 Fig. 4A Possible pathways for formation of Advanced Glycation End products, AGEs.  
 
 
(corrected from www.google.no) 
 
The formation of AGEs occurs in most foods during heating and plays a central role in the 
development of color, aroma and flavor, texture and nutritional value of cooked and processed 
foods.  
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However, these processes were later also revealed in biological systems. 
HbA1c, which reflects mean level of blood glucose, is an Amadori product (see Fig. 4A) and 
the most important predictor for development and progression of vascular complications in 
diabetes (21) (19).  
 
AGEs; definition and examples  
The term “AGEs” refers to posttranslationally glycated modifications on end-standing 
aminogroups on proteins, lipoproteins, lipids and nucleic acids that non-enzymatically have 
undergone irreversible dehydration and condensation processes via various reactive 
intermediates. There may be several modifications per molecule and several different proteins 
may be modified. The modification itself is often referred to as an “adduct”. (see Fig. 4A). 
There are several alternative routes into forming AGEs, and the predominant substrate 
fuelling the glycation is glucose. However, carbohydrates and sugars other than glucose, such 
as glyceraldehyde, fructose and ribose also glycate to form AGEs.  
Early glycation products may later form advanced glycation end products, like glyoxal from 
auto-oxidative glycation. Glyoxal may, through further steps of oxidation (glycoxidation) 
form N-(carboxymethyl)lysine (CML), whereas methylglyoxal (MG) may form 
hydroimidazolones and e.g. argpyrimidine. MG levels are increased in diabetes, and 
hydroimidazolone is one of the most important AGEs (87). CML and other AGEs may also 
form without carbohydrates from lipid peroxidation, phospholipids and the nucleotides of 
DNA. When oxidation accompanies glycation, examples of additional glycoxidation products 
to CML are CEL and pentosidine, the latter with intrinsic fluorescent properties (80). Tissue 
and plasma fluorescence may be used as indirect markers of accumulation of AGEs. In 
addition to CML and pentosidine, glyoxal-lysine dimer (GOLD) is considered marker of 
glycoxidation (88).   
Examples of AGEs formed through nonoxidative processes are pyrraline, MOLD and DOLD. 
A list of biologically important AGEs are found in Table 1 (89). 
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Methylglyoxal derived AGEs  
In addition to sugars, many different aldehydes and ketones can form AGEs in vivo. 
Methylglyoxal (MG) is an -oxoaldehyde capable of provoking oxidative stress, and is 
present at higher concentrations in diabetes (90). It generates from spontaneous 
decomposition of triose-phosphate intermediates in aerobic glycolysis and oxidative 
degradation of both carbohydrates (pentoses and ascorbate) and lipids (arachidonate) (91). It 
is also a substrate of the glyoxalase system (92), which detoxifies it to D-lactate. 
By irreversible glycation, methylglyoxal forms AGEs both intracellularly and extracellularly. 
It may modify a range of different proteins in different compartments, from collagen in tissue 
to proteins of the circulation. The type of AGE modification formed is determined by the free 
aminogroup to which it binds and modifies.  
There are three main aminoacids that react non-enzymatically with methylglyoxal forming 
physiological AGEs; cysteine, lysine and arginine.  
Examples of cysteine modifications are CMC and CEC, which are increased in plasma of 
diabetic nephropathy (93).  
N(epsilon)-(carboxyethyl)lysine (CEL)  and the imidazolium crosslink, methylglyoxal-lysine 
dimer (MOLD) are examples of AGEs formed from MG and lysine. Lysine modifications 
may also crosslink with eachother via lysine bridging forming imidozolysine.  
When MG reacts with arginine, argpyrimidine may form, which is a fluorescent AGE. 
However, the main AGEs formed when MG reacts with arginine in proteins are isomers of 
hydroimidazolone called methylglyoxal hydroimidazolones, of which MG-H1 (N--acetyl-N-
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-(5-hydro-5-methyl)-4-imidazolone is the one quantitatively dominating in vivo, often 
referred to as hydroimidazolone only, and of special focus of this thesis 
(See Fig. 4B). 
 
 
 
 
AGEs and disease  
The formation of AGEs is observed in the human body at all ages and increases as a process 
of normal aging, contributing to cross-linking of extracellular, long-lived proteins, and may 
lead to browning and fluorescence, and – where these reactions are accelerated – to 
development of diabetic complications and inflammatory processes linked to 
neurodegenerative diseases (94), hypertension, rheumatoid arthritis and atherosclerosis (95).  
There are several reasons for AGEs believed to be of pathogenic importance in diabetic 
vascular complications (see Table 2): 
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Table 2.  
Background for pathogenic involvement of AGEs in vascular complications of diabetes. 
Pathogenic importance AGEs / findings References
AGEs  measured in skin collagen from 
human biopsies predict progression of 
diabetic microvascular complications better 
than HbA1c 
CML (96) 
Injection of AGE modified proteins in non-
diabetic experimental animals produces 
effects similar to diabetic late complications 
in vitro modified rat serum 
albumin 
(97) 
Inhibition of AGEs reduces diabetic 
retinopathy, nephropathy and neuropathy in 
experimental animals 
PAS-positive vasculature 
deposits in hypertensive 
rats / Radioimmunoassay-
AGEs measured as AGE-
RNase per μmol 
hydroxyproline and  tissue 
fluorescence in end organ 
of diabetic rats 
(98) (99) 
(100) 
A positive correlation has been shown 
between content of AGEs in human skin 
collagen and diabetic retinopathy and 
nephropathy 
ELISA for skin collagen 
AGEs; pentosidine and 
fluorescent AGE 
measurements / 
fructoselysine, CML, 
pentosidine and 
fluorescence 
(101) (102) 
Associations have been found between 
serum levels of AGEs and human diabetic 
nephropathy and cardiovascular disease 
AGEs with DELFIA and 
polyclonal antibody / non-
CML AGEs 
(103) (104) 
AGE receptor interactions  (see under next italic headline) 
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Figure 5 depicts the three routes as mentioned in 6.3 IV 1-3, through which AGEs may cause 
cellular dysfunction:  
 
 
 
Circulating AGEs; AGE/RAGE interaction 
The liver and kidney are both involved in the catabolism and excretion of AGEs from the 
circulation (105) (106). Renal tissue is among the targets of AGEs that cause cellular damage 
and reduce kidney function. Hence, a reduced clearance of AGEs from the circulation may 
further increase both cause and effect of damage from glycation (107). Clinical studies have 
reported increased serum levels of CML in subjects with type 1- (108) and type 2-diabetes 
(90) and elevated levels of CML are associated with microvascular complications of diabetes 
such as retinopathy (101). In addition, patients with type 2-diabetes have increased circulating 
levels of the AGE hydroimidazolone (109) and its precursor MG (90). Positive associations 
between serum levels of hydroimidazolone and retinopathy have been shown in clinical 
studies of type 1-diabetes (110). The effects of circulating AGEs may be caused by interaction 
with receptors or without receptors involved (See Fig. 5). There are several AGE receptors, of 
which the multiligand receptor RAGE probably is among the most important, participating in 
chronic inflammatory and immune responses (111). Proposed endogenous ligands for RAGE 
other than certain AGEs (like CML), are S100/calgranulins (a family of closely related 
calcium-binding polypeptides that accumulate extracellularly at sites of chronic 
inflammation); amphoterin (or protein HMGB1, released by cells undergoing necrosis) and 
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amyloid (amyloid - peptide accumulating in Alzheimer’s disease; amyloid A accumulating 
in systemic amyloidosis).  
A truncated, soluble form of RAGE also exists; sRAGE (endogenous secretory 
RAGE), which is capable of binding extracellular ligands without cell contact. sRAGE in 
excess can competitively bind ligands meant for RAGE, thus preventing cellular signalling 
mediated via this receptor. The balance between levels and actions of RAGE and sRAGE may 
be central in AGE-mediated pathology (80). AGE/RAGE interaction activates a cascade of 
signal transductions, of which the PKC pathway is one. Generation of reactive oxygen species 
(ROS) may follow, triggering NF-B. This in turn elicits release of proinflammatory 
cytokines, expression of adhesion molecules and growth factors (e.g. VCAM-1, TGF-B1, 
VEGF), all implicated in the pathogenesis of diabetic complications, like diabetic retinopathy 
(111) (80).  
Whether hydroimidazolones interact with RAGE is uncertain. However, methylglyoxal 
modification of arginine residues by may be particularly damaging because arginine residues 
occur at a high frequency in substrate and ligand recognition sites in enzymes and receptors 
(112). 
 
AGEs, VEGF and the eye  
Retinal pericytes have a low regenerative capacity. Loss of these supportive cells is an early 
event in the course of diabetic retinopathy (48). As AGEs in vitro are toxic to bovine retinal 
pericytes and cells of the microvasculature (113) (114), they may play an important role in 
pericyte loss. Further, capillary non-perfusion and closure gradually increase hypoxia and 
stimulation of growth factors (Fig. 1). VEGF is produced in the eye by retinal pigment 
epithelium (RPE) cells and is up-regulated by hypoxia. It is considered to be involved in the 
progression of diabetic retinopathy (115) (116) as it stimulates vascular permeability and new 
vessel growth. It has been shown that AGEs induce VEGF expression in retinal cell culture 
and animals. There are four major biologically active human isoforms. VEGF165 
predominates in the human eye, appearing to be responsible for pathological ocular 
neovascularization (117). If AGE modified protein is injected in non-diabetic rats, VEGF in 
the eye is up-regulated (118), producing dysfunction of the inner BRB (119). Utilizing “anti-
VEGF” as a therapeutic concept has expanded over the last few years: VEGF antibodies are 
used to reduce neovascularization and edema of not only cancer but also ophthalmologic 
entities such as AMD and ME of DR (120) (121).  
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Interestingly, AGEs are associated with degenerative changes of other tissues of the 
eye as well:  
-  Accumulation of AGEs (CML) is found on the corneal basement membrane suggesting a 
causative role in corneal epithelial disorders in diabetes (122).   
-  Methylglyoxal hydroimidazolones are quantitatively major AGEs of the lens proteins in 
humans. These lens protein modifications may stimulate further glycation, oxidation, and 
protein aggregation to form cataract (123). 
-  Accumulation of AGEs (pyrraline) is found at the optics disc; in the cribriform plate and 
around vessels of the optic nerve, possibly contributing to the development of neuropathy of 
the optic disc and nerve in diabetes (124). 
-  Elevated levels of AGEs (non-CML, hydroimidazolone) have recently been described in the 
human vitreous of diabetic patients compared to non-diabetic controls (125) (126). 
 
 
 AGEs; different methods for detection  
1)  Immunoassays are widely used in the field of AGE research. The immunoassay used in the 
present study was developed by Kilhovd et al (109) based on work by Berg et al with minor 
modifications (110) in our determination of N-acetyl-N-(5-hydro-5-methyl)-4-imidazolone 
(MG-H1) which is a  methylglyoxal (MG) -modified arginine compound. The antibodies of 
the DELFIA assay (dissociation enhanced lanthanide fluoro-immunoassay) used are marked 
with Europium chelate for fluorimetric visualization. An advantage of the DELFIA system 
compared to the enzyme linked immunoassay (ELISA) is its ability to diminish interfering 
background fluorescence when applying a delayed fluorescent visualization technique. With 
either immunoassay the quantification is relative, depending on the quality of the standard 
quantification.  
 
2)  Separation methods coupled to MS (mass spectrometry):  Due to the complexity of 
biological samples, chromatographic techniques (e.g. HPLC; high pressure liquid 
chromatography) have been used for initial separation of molecules into relatively 
homogenous groups. This may be used in combination with later, spectrometric methods, 
such as LC-MS (liquid chromatography mass spectrometry). MS may be performed in a 
coupled fashion called MS/MS, or tandem mass spectrometry. These are all methods for a 
more absolute quantification with a relatively high sensitivity. 
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With mass spectrometry (MS), the constituents of chemical samples are measured as the 
mass-to-charge ratio of ions: The sample is ionized; ions of different masses are separated, 
and finally; their relative abundance is measured by ion flux intensity. This is the golden 
standard for AGE measurements at the present time. However, initial preparation of the AGE 
sample is still necessary before LC-MSMS (127), usually by enzymatic digestion or acid 
hydrolysis. This implies that the intact modification of the protein is not measured, but rather 
peptide fragments of the modified proteins. 
  
3)  Autofluorescence may be measured using an autofluorescence meter applied to the skin 
(128). This method is not AGE specific, as compounds other than AGEs also may fluoresce. 
It measures both glycation and oxidation adduct fluorophores, but the phenomenon of 
fluorescence in tissue and plasma can be used as a marker for the presence of AGEs. Over 
time, tissue fluorescence increases in diabetes (83), (129), (130) as observed within the 
kidney, the retina, the skin and other sites of diabetic microvascular pathology. Some studies 
have suggested that fluorescent AGEs may be better associated with microvascular 
complications than with non-fluorescent compounds such as CML (131). It is thought that 
incomplete degradation of AGE-modified proteins from the diet or endogenous sources 
produce so called low–molecular weight (LMW) AGEs. A simple and indirect way of 
measuring tissue florescence is by measuring fluorescence in the LMW fraction of serum 
(108). The findings of Januszewski et al support the association between LMW AGEs and 
end-organ damage in diabetes (132). 
 
6. Aims of research 
 To measure and stepwise compare serum hydroimidazolone within a group of diabetic 
patients with different degree of retinopathy  
 To measure and compare in patients with diabetes and in age matched controls: 
- hydroimidazolone in vitreous of patients with diabetes and in age matched 
controls   
- hydroimidazolone and VEGF both in serum and in vitreous fluid 
 To compare retinopathy from fundus photographs in a follow-up study of patients with type 1 
diabetes  
 To apply a new, clinical method of retinopathy classification on fundus photographs 
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7. Subjects and methods 
 
7.1 Subjects 
Paper 1 
From a Scandinavian outpatient clinic we recruited 227 patients with type 2 diabetes mellitus 
– 124 men and 103 women – with retinopathy ranging from none to proliferative. At the time 
of diagnosis, 221 patients were older than 30 years and 6 patients were younger than 30 years, 
but were not in need of insulin treatment. 86 had no retinopathy; 89 had NPDR and 52 had 
PDR. The retinopathy group (NPDR + PDR) was cross-sectionally compared to the non-
retinopathy group (DNR). The two groups differed significantly on several parameters; hence 
logistic regression analysis was applied for comparison regarding retinopathy and serum 
levels of hydroimidazolone. Patients with plasma creatinine values > 200 mg/dl were 
excluded as this level of reduced kidney function may be associated with increased serum 
hydroimidazolone values. 
 
Paper 2 
Vitreous from 23 consecutive patients with type 2-diabetes and median known diabetes 
duration of 12 years were included and compared to 32 non-diabetic and age-matched control 
subjects who also underwent vitrectomy. The median age of both groups was 67 years. 
Vitrectomy within the last 6 months before hospitalization and vitreous of reddish colour were 
criteria for exclusion; as were plasma creatinine values > 200 mg/dl. Serum and vitreous 
parameters were cross-sectionally compared with regard to hydroimidazolone and 
retinopathy, in particular. 
 
Paper 3 
We randomly selected 61 patients with diabetes mellitus type 1 from a Scandinavian 
outpatient clinic for comparison of degree of retinopathy and serum levels of 
hydroimidazolone. DNR patients had a mean duration of diabetes of 14 years, which was 
significantly lower than the mean duration of 20 years in the DR group. The ratio PDR/NPDR 
was 36/11. Quartiles of serum hydroimidazolone were compared with occurrence of 
retinopathy.  
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Paper 4 
In 1989, of the reachable 1868 incident type 1 diabetes cases in Norway from the period 
between 1973 and 1982, 600 were randomly selected for participation in the study. The 
baseline examination for diabetic complications of the 368 enrolled took place in 1989/-90. 
355 were eligible for follow-up examination in 2002/-03.  
All new-onset cases of type 1 diabetes occurring in Norwegian children below 15 years of age 
within the decade 1973/-82 were retrospectively registered by the Norwegian Childhood 
Registry between 1985 and 1986. The analyses at follow-up included 294 subjects with 
proper retinal photographs. The participants belonged to different hospital catchment areas, 
and the main investigator visited 24 different hospitals all over Norway. The examination 
included a medical history, blood pressure measurements, collection of overnight timed urine, 
random venous blood samples and fundus photography. Patient characteristics at baseline, 
divided into participants and non-participants at follow-up, were compared. 
   
 
7.2 Methods 
MG modification of BSA was prepared by incubating BSA in sodium phosphate buffer (100 
mM, pH 7.4 and 37	C) with 1 mM MG for 4 days, before dialyzed against ammonium 
bicarbonate buffer (30 mM, pH 7.9 and 4	C) and lyophilized to dryness. Preparations of 
lyophilized MG-BSA were stored in liquid nitrogen. As determined by Thornalley’s group 
(133) using HPLC amino acid analysis, this low-modified MG-BSA contains 23% modified 
arginine residues per molecule of serum albumin. 
 
Hydroimidazolone immunoassay  
We have previously developed specific solid-phase, time-resolved competitive immunoassays 
(DELFIA Wallac, Turku, Finland) for determining AGEs in serum (103); further developed 
by Kilhovd et al (109). The primary antiserum of the assay is a monoclonal anti-
hydroimidazolone (IG7) antiserum. (It was obtained by injecting mice with keyhole limpet 
haemocyanin (KHL) and modified by incubating with 70 mmol/l of MG for 6 hours at 37	C. 
Epitope specificity of the anti-hydroimidazolone antibody was evaluated using both dot blots 
and an indirect competitive ELISA. The IG7 antibody reacted specifically with N-acetyl-N-
(5-hydro-5-methyl)-4-imidazolone, showed 1% cross-reaction against its oxidized form 
methylimidazolone, and to some extent recognized the analogue glyoxal derived arginine 
hydroimidazolone compound. It did not react with N-acetyl-argpyrimidine, bis(N-
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acetyl)lys-4-methyl-imidazolium chloride or carboxyethyllysine.) The IG7 antibody relatively 
specifically recognized MG-induced modifications of arginine residues, and did not cross-
react with the imidazolones produced by the reaction of 3-deoxyglucosone with arginine 
(134), (135). 
Essentially as described by Kilhovd et al (109), levels of hydroimidazolone immunoreactivity 
were determined with this monoclonal anti-MG-modified arginine antibody, except that we 
coated the microtiter wells in 0.05 mol/L Tris buffer (pH 7.8) and set up our assay in 
duplicates: Microtiter strips of 12 wells each were coated with 0.1 ml of MG-modified BSA 
(25 
g/ml) diluted in 0.05 mol/L Tris buffer (pH 7.8). They were then covered, and incubated 
overnight while shaking at room temperature. The strips were further stored at 4	C before 
washed. The wells were washed 6 times in DELFIA washing buffer before use. Duplicates of 
100 
l MG-modified BSA standard or serum (diluted 1:4) were added to each well along with 
50 
l of anti-hydroimidazolone (IG7) antiserum diluted 1:5000 in DELFIA assay buffer*. 7 
standard solutions of 0, 2.5, 5, 10, 20, 40 and 100 
g/ml MG modified BSA were used per 
assay. The strips were incubated while shaking in room temperature for two hours, and then 
washed six times in washing buffer. 100
l/well of Europium-labeled anti-mouse-IgG-
antibodies were then added in a final concentration of 0.1 
g/ml in DELFIA assay buffer. 
(The indicator antibody for the DELFIA was marked with Europium chelate for fluorimetric 
visualization). All strips were incubated while shaking for one hour in room temperature, 
before subsequently washed 6 times and incubated for 5 minutes while shaking with DELFIA 
Enhancement solution prior to measurement of the Europium-ion chelate specific 
fluorescence in a 1232 DELFIA Fluorometer.    
This assay was applied in paper 1, 2 and 3. The arbitrary hydroimidazolone unit (U) was 
defined as the competitive activity of 1 
g of MG-modified BSA standard, expressed as U/mg 
protein. 
                                                                                                                                            
*When determining vitreous levels of hydroimidazolone, the same assay was used. Vitreous 
samples were set up in non-diluted triplicates. 
 
VEGF assay  
We determined serum and vitreous levels of the angiogenic isoforms of natural human 
VEGF165. The Quantikine ® VEGF immunoassay (R & D Systems, Inc., Minneapolis, MN, 
USA) was used. Optical density was determined at 450 nm using a Rosys Anthos HT2 micro 
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plate absorption spectrophotometer (Anthos Labtec Instruments, Salzburg, Austria). A 
correction wavelength of 620 nm was used.  
 
Vitreous hemoglobin  
Harboe’s method together with updated validations for measuring haemoglobin (Hb) in 
micromolar concentrations were used (136). We measured absorbance with an Ultrospec® 
3300 pro spectrophotometer (Amersham Biosciences, Cambridge, UK; acquired by General 
Electric Company, Fair- field, CT, USA) at wavelengths of 380 nm, 415 nm and 450 nm. The 
following equation then expresses in g l the concentration of hemoglobin (137): CHb = 1.67 x 
A415 – 0.83 x A380 - 0.83 x A450.  
 
Vitreous albumin  
Albumin was measured in duplicates of 50 
l vitreous samples using the Tina-quant 
immunoturbidimetric albumin assay (F. Hoffmann-La- Roche Ltd, Basel, Switzerland). 
 
 
Asessment of Retinopathy 
Paper I & Paper III: After pupillary dilation, stereo photographs from 7 standard fields were 
taken of each eye, using a 30	 fundus camera (Topcon TRC-50, Tokyo, Japan). Grading was 
performed in a masked fashion. The patients were characterized according to the ETDRS 
level of retinopathy in the worse affected eye by a centrally located, highly skilled team. If 
former treatment with panretinal photocoagulation had been given, retinopathy was 
automatically classified as PDR; that is, ETDRS level 61. 
We then grouped these results in three categories: DNR, NPDR and PDR for comparison of 
retinopathy with other parameters. 
Paper II:  The patients were clinically diagnosed during their period of hospitalization: 
Diagnoses were pre- and peroperatively confirmed by the eye surgeon through mydriatic 
pupils, using indirect ophthalmoscope and operating microscope, respectively. 
Paper IV: In paper 4, the photographic procedure of taking colour retinal photographs of 
each eye using Kodachrome 64 ISO 35-mm colour slide film (Kodak, Rochester, NY, USA) 
with a non-mydriatic 45	 retinal camera (45NM-CR; Canon, Tokyo, Japan) was applied by 
the same investigator (T. Skrivarhaug) after instilling one drop of cyclopentolate 1% and 
epinephrine 10% in the cul-de-sac of each eye to obtain dilated pupils. The standard 
procedure of centering the photographs midway between the fovea and the temporal edge of 
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the optic disc was executed in the exact same way at follow-up and baseline. For back-up 
safety in case of reduced quality affecting the readability of one or more pictures, double sets 
of pictures were taken of each eye. Without knowledge of the subjects’ identity, the pictures 
were graded centrally for retinopathy (by D. Fosmark), status of the worse eye deciding level 
of retinopathy. Between the extremes PDR and DNR; NPDR was further sub-classified with a 
new, simplified clinical method (Table 1) based on evidence from the ETDRS and the 
WESDR (Diabetic Retinopathy Disease Severity Scale (75)). Macular edema was not 
detectable using our method. Patients with fibrous proliferations, vitreous hemorrhage or scars 
from panretinal photocoagulation were assigned to the PDR category.  
 
HbA1c was analyzed with high-performance liquid chromatography (VARIAN II 
Hemoglobin A1c program, BioRad, Hercules, CA) (reference range, 4.0%-5.3%). 
 
 (Blood tests were collected after overnight fasting. 
 
Three overnight timed urine samples were collected at home. 
       
Creatinine in urine was analyzed using a kinetic method (Beckman Synchron LX20, Brea, 
CA). 
 
Urinary albumin was measured using nephelometry (IMMAGE, Beckman Coulter) or 
turbidimetry (Beckman Synchron LX20). Normal values for urine albumin urine creatinine 
ratio were < 2.0 mg/mmol for men and < 2.8 mg/mmol for women. 
 
Plasma creatinine was analyzed with a kinetic method (Beckman Synchron LX20). The  
Reference ranges are 51- 88 
mol/L (women) and 63-105 
mol/L (men). 
 
Lipids (triglycerides and total cholesterol) were measured with standard enzymatic methods at 
a centralized lab. 
Statistical analyses  
In all papers, statistical analyses were performed using the SPSS software, version 12.0.0 
(SPSS, Chicago, IL). Two-sided Mann-Whitney U test was used when comparing medians of 
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continuous data not normally distributed. The Spearman correlation test was used when 
studying the association between two continuous variables. For conservative estimates, we 
used logistic regression analysis according to Katz (138). A significance level of 5% was used 
for each test. 
Paper I: Unadjusted comparisons between patients with and without retinopathy were 
performed using Student’s t-tests (2-sided) for continuous variables and exact Fisher tests (2-
sided) for dichotomous variables. Logistic regression analysis, with retinopathy as dependent 
variable, was used to study the impact of selected variables; hydroimidazolone, plasma 
creatinine, urinary albumin-creatinine ratio, HbA1c, diabetes duration, age, and blood 
pressure. (These variables were enabled for multiple regression analyses as initial bivariate 
unadjusted analyses showed significant associations with retinopathy). 
Paper II: Spearman’s test for correlations was used for correlation testing. Logistic 
regression was used for correction of vitreous albumin when comparing vitreous VEGF 
between controls and diabetes patients. 
Paper III: A linear-by-linear association chi-square test was used when studying the 
association between quartiles of hydroimidazolone and retinopathy. We used a two-sided 
exact Fisher test when comparing the prevalence of retinopathy between two groups. When 
comparing HbA1c and age between two groups, an independent two-sample t-test was used; 
and for the comparison of duration of diabetes, a two-sided Mann-Whitney test was used. The 
Spearman correlation test was used when studying the association between two continuous 
variables.  
Paper IV: We estimated the cumulative incidence of PDR from diabetes onset until follow-
up, using a Kaplan-Meier plot. To assess declining incidence of PDR with year of diagnosis, 
the patients were divided into two groups: 1973–1977 (n=133) and 1978–1982 (n=161). Cox 
regression analysis was used to estimate the hazard ratio for association between baseline 
factors and PDR. The following variables were analyzed: sex, age, age at diabetes onset, 
diabetes duration, smoking status, arterial blood pressure, AER, HbA1c, triglycerides and 
total cholesterol. Variables with a p-value <0.20 were then included simultaneously in a 
multiple regression model.  
In the analysis of predictive risk factors for PDR, the three subjects with PDR at baseline were 
not included. As the exact time of onset of NPDR was unknown, the assessment of potential 
predictors of retinopathy among patients without DR at baseline was analyzed similarly using 
logistic regression.  
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Sensitivity analysis of non-participation was exclusively based on HbA1c values. By using 
assumptions based on external data, we performed a sensitivity analysis in order to assess the 
potential influence of selection bias due to non-participation and other losses to follow-up 
(deaths and emigration) on our estimated risk of complications. The total risk in the full 
cohort of participants and non-participants is a weighted average of the observed risk of 
complications among participants and the corresponding risk among non-participants. This 
total risk can then be estimated under conservative assumptions regarding the risk among non-
participants. 
(Data from the DCCT indicated a 75% increase in risk of PDR per 1%-point increase in 
HbA1c during a mean follow-up of 6.5 years. The HbA1c difference among non-participants 
and participants in our material in 1990 was only 0.6%-points. A conservative assumption of 
75% higher risk of PDR as compared with the participants was made, and that 50% of them 
had no DR at baseline while the rest had NPDR.) 
 
8. Summary of main results (papers) 
 
Paper 1:   
 Increased serum levels of the specific advanced glycation end product methylglyoxal-derived 
hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus. 
 
According to the ETDRS protocol, level of retinopathy was determined from retinal 
photographs of 227 patients with type 2 diabetes mellitus and median known diabetes 
duration of 14 years. 86 patients had no retinopathy (DNR), whereas non-proliferative 
retinopathy (NPDR) was diagnosed in 86 patients and proliferative retinopathy (PDR) in 52 
patients. Median age was 66 years.  
Serum levels of hydroimidazolone were increased in the group of patients with retinopathy, 
with a further increment as retinopathy worsened to PDR. This was found when including all 
patients irrespective of time elapsed from diabetes having been diagnosed, but also in the 
smaller group of patients with shorter duration of diabetes, i.e. below the median of 14 years. 
We found a strong association between HbA1c and diabetic retinopathy (p<0.0001), and the 
association between retinopathy and hydroimidazolone was independent of HbA1c.  
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Paper 2:  
 Increased vitreous levels of hydroimidazolone in type 2 diabetes patients are associated with retinopathy. 
 
Using a cross-sectional case-control study design, we compared vitreous and serum contents 
in 23 patients with diabetes type 2 – sixteen of which had PDR – to 32 age-matched controls 
also undergoing vitrectomy. Level of retinopathy was based on clinical examination. We 
found a positive correlation in all patients between vitreous and serum content of 
hydroimidazolone (r=0.48, p<0.001). This was also true within cases and non-cases 
separately.  
  
Paper 3: 
 Serum levels of the Advanced Glycation End product hydroimidazolone is associated with retinopathy 
occurrence in type 1 diabetes patients.  
 
In this cross-sectional study of 61 type 1 diabetic patients, 14 had no retinopathy (DNR), 11 
had NPDR and 36 had PDR. Grading of retinopathy was based on retinal 7-field stereo 
photographs according to the ETDRS protocol. Comparisons of serum levels of 
hydroimidazolone were made between patients with and without retinopathy. 
Hydroimidazolone quartiles were found significantly associated with retinopathy (p=0.013). 
After adjusting for duration of diabetes by logistic regression analysis, a significant difference 
in retinopathy present was found when comparing the lowest quartile with the rest (p=0.022).  
 
Paper 4:  
 Low cumulative incidence of proliferative retinopathy in childhood-onset type 1 diabetes in Norway. 
 
294 childhood-onset type1 diabetic patients had readable fundus photographs taken and 
examined for retinopathy between 2002 and 2003. This was a follow-up of originally 368 
patients having undergone identical examinations between 1989 and 1990; all belonging to 
the 10 year cohort of 1906 persons diagnosed with diabetes mellitus type 1 between 1972 and 
1983. 262 of 294 (89.1%) developed diabetic retinopathy, of which 32 developed PDR. The 
cumulative incidence of PDR began increasing after 10 years of diabetes duration, reaching 
10.9 % (95 % CI: 7.3-14.5 %) at twenty-five years. Mean diabetes duration was 19 years 
(range 12-29 years); mean age for diagnosis of PDR was 27 years (range 17-41 years). 
Significant predictors at baseline for developing retinopathy of any degree were HbA1c 
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(OR=3.25, 95 % CI: 1.76-6.02, p<0.001) and male gender (OR=2.51, 95 % CI: 1.06-6.00, 
p=0.037), whereas significant predictors for developing PDR were NPDR at baseline 
(RR=3.71, 95 % CI: 1.59-8.68, p=0.03), HbA1c (RR=2.05, 1.44-2.93, p<0.001) and 
triglycerides (RR=1.55, 1.06-1.95, p=0.019).    
 
9. Discussion 
9.1 Methods 
Clinical and Photographic methods of retinopathy diagnosis 
 
a) The “Gold standard” for epidemiological surveys of DR is the seven-field, (analogue) 
retinal photographic method using film and a 30	 camera. Members of a highly skilled team, 
centrally located with resources at hand, applied this method on the subjects in paper 1 and 3, 
including later grading of the pictures according to the ETDRS standard. We grouped these 
results in three categories: DNR, NPDR and PDR for comparison of retinopathy with other 
parameters. 
  
b) In paper 4, to obtain dilated pupils one drop of cyclopentolate 1% and epinephrine 10% 
was instilled in the cul-de-sac of each eye. The non-mydriatic 45	 retinal camera (45NM-CR; 
Canon, Tokyo, Japan) produced colour retinal photographs of each eye using Kodachrome 64 
ISO 35-mm colour slide film (Kodak, Rochester, NY, USA). The photographic procedure was 
applied by the same investigator (T. Skrivarhaug). The standard procedure of centering the 
photographs midway between the fovea and the temporal edge of the optic disc was 
performed in the exact same way at baseline and follow-up. For back-up safety in case of 
reduced quality affecting the readability of one or more pictures, double sets of pictures were 
taken of each eye. Without knowledge of the subjects’ identity, the pictures were graded 
centrally for retinopathy (by D. Fosmark), status of the worse eye deciding level of 
retinopathy. Between the extremes PDR and DNR, NPDR was further sub-classified with a 
new, simplified clinical method (Table 1) (75). Macular edema was not detectable using our 
method. Patients with fibrous proliferations, vitreous hemorrhage or scars from panretinal 
photocoagulation were assigned to the PDR category. 
 
c) In paper 2, all ophthalmologic diagnoses including retinopathy were given during the 
patients’ period of hospitalization. The diagnoses were pre- and peroperatively confirmed by 
the eye surgeon using indirect ophthalmoscopy and operating microscopy, respectively. 
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When we chose methods for comparison of retinal photographs in paper 4, digital 
cameras were about to substitute the use of analogue equipment – including film. Yet, the 
extensively marketed digital techniques with resolution constantly improving, a standardized 
comparison with analogue photographs was missing. Hence, at follow-up, the described one-
field method for film was chosen due not only to its simplicity, but because of identicality to 
the method originally used at baseline. This facilitates the comparison between the two 
investigations.  
A more detailed yet standardized method for further classification of late changes in 
the course of retinopathy development was needed. An improved clinical method, newly 
developed in order to simplify the existing 7-field ETDRS Gold standard and to facilitate data 
comparisons between different countries and trials, was found applicable for our purpose.     
Albeit subjective, the clinical standard for identification of patients with retinopathy is by 
direct ophthalmoscopy. However, images from cameras producing single 30	 and 45	 fields 
have both been considered useful for retinopathy screening, epidemiology studies and routine 
care purposes. An exact agreement of 82.5 % was found when comparing ophthalmoscopy to 
the seven field stereo photographic method (139).  
Our method using a single 45	 photograph can be criticized for the possibility of under-
detecting retinopathy. One relative advantage with the 45	 field is that only one photo is 
needed to view the posterior pole of the retina. However, it is of lower magnification than (the 
one) produced with a 30	 camera (minified 0.64x at zero diopters). The 45	 images include 
areas above and below the temporal arcades, and temporal to the macula and just nasal to the 
disc (see Fig. 6). 
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Fig. 6  Approximate field obtained with a 45	 camera superimposed (dotted lines)  
              on photographic field obtained with the standard seven-field mydriatic stereoscopic  
              protocol from the Early Treatment Diabetic Retinopathy Study and a 30	fundus camera  
              (field 1 = disc; field 2 = macula; field 3 = temporal to macula; field 4 = superior temporal;  
              field 5 = inferotemporal; field 6 = superior nasal; field 7 = inferior nasal). 
 
With the use of a digital, monochrome camera, a study on retinopathy in 197 type 1 and type 
2 diabetic patients with a single 45	 image versus ophthalmoscopy revealed 100% sensitivity 
and 71 % specificity, the field identical to the field in our study (paper 4). Compared to the 7 
field stereo photographic method, the sensitivity and specificity of the 45	 image were 78 % 
and 86 %, respectively, with an exact agreement of 83 % (140). 
New vessels in the periphery only are very rare (<1 %), and new vessels at the posterior pole 
(in patients younger than 60 years) are significantly more frequent than beyond the posterior 
pole (141). Thus, a one-field photo of each eye covers most of the area of interest for 
inclusion of PDR-diagnoses. Predilection sites for retinal proliferations are the temporal 
arcades and second, the area nasal to the optic disc (142) (141).  
In order to cover a larger retinal area, a two field photographic method with an identical 45	 
NM-Canon camera has been validated over a 5 year period; centered on the macula and the 
optic disc, respectively (141). Missed diagnoses of PDR amounted to 0.9 %. False positive 
findings occurred in 6 of 1341 readings, or 0.4 %. False NVD were recorded mostly in 
younger patients (36 years), whereas false NVE were recorded mostly in older patients (50 
years). True NVE/NVD were found located on the temporal arcades in 48 % of the eyes and 
nasally to the optic disc in 42 % of the eyes, and were rarely found beyond the posterior pole 
(13 %; p<0.001) (141).  
 35
In retrospect, the two-field method might also have been applied in our setting. A larger area, 
particularly nasally to the optic disc, would then have been included. Still, macular edema 
would not have been classifiable. However, the one-field method was found sufficient for our 
purpose; to classify a larger group epidemiologically, and was chosen due to comparisons to 
be made with identical field pictures. The better of two photographs from both eyes was 
graded before the diagnosis was given by the state of the worse eye, but a small fraction of 
false negative PDR with our method due to a lower sensitivity is possible. However, a 
possibility of having undergone laser treatment without PDR also exists, overestimating this 
group. Importantly, in our material 78.6% had NPDR; of these most had mild NPDR (54.6%). 
Further, moderate NPDR accounted for 32.4% and severe NPDR amounted to only 13.0%. 
This clustering of relatively benign retinopathy is in keeping with our conclusion of a 
relatively low cumulative incidence of PDR after 25 years of diabetes. The pictures were 
thoroughly graded by one experienced ophthalmologist (D. Fosmark) in one session only. 
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Immunoassay method 
Different methods have been developed and used for the detection of AGEs within the field of 
research. For the detection of the hydroimidazolone MG-H1, the DELFIA-system was chosen 
due to experience regarding development and use in our laboratory. The quantification of 
AGEs when using immunoassays gives relative results, partly due to a missing quantitative 
standard for the different AGEs. Arbitrary units are therefore employed. Our assay for 
detection had an intra-assay variation in the range of 12 – 15%. The inter-assay variation was 
of up to 21%. The cross-reactivity against AGE-BSA was 8% when calculated as AGE-BSA 
protein against MG-modified BSA protein. No cross-reactivity was found against CML-BSA 
or glycated albumin in the hydroimidazolone immunoassay. The IG7 antibody relatively 
specifically recognizes MG-induced modifications of arginine residues. 
In use, the assay is practical as it is inexpensive, and many samples can be run within a 
relatively short period of time. It is also sufficient for our purpose, which is in larger samples 
to search for significant differences between cases and controls. Immunoassays have been 
criticized for their heavily modified antigen, use of arbitrary units and possible serum effects 
(87). However, the present assay has an acceptable dilution curve and satisfactory recovery   
(135): Both serum samples from diabetic patients and controls produced parallel inhibition to 
hydroimidazolone standard. Recovery studies have been performed by adding MG modified 
BSA to serum from patients and controls. The mean recovery of amount added was 115% ± 
26 %-points. A linear dilution curve reflected minor serum effect.  
One advantage of the DELFIA system compared to other immunoassay methods (ELISA) is 
its ability to diminish the background fluorescence through delayed fluorescence from 
Europium attached to the secondary antibody. Hydroimidazolone (MG-H1) is our AGE 
modification of focal interest due to its relative abundance in biological systems and its 
likelihood of playing a pathogenic role in diabetic complications.  
 
9.2 Interpretation of results  
For each paper, thorough interpretations are found in their respective sections of discussion 
(See Papers 1, 2, 3 and 4). In Paper 1 and 3, there exists a positive association between 
retinopathy and serum levels of hydroimidazolone in both type 2 and type 1 diabetes. 
However, as the studies are cross-sectional, no causal conclusions can be made. The lack of 
association between HbA1c and hydroimidazolone is in keeping with earlier findings; and 
logical, as the two are formed via partly different pathways. However, it is noteworthy that 
both hydroimidazolone and HbA1c were found strongly and independently associated with 
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retinopathy. Patients with clearly increased serum creatinine (>200 μmol/l) had not 
surprisingly clearly elevated serum hydroimidazolone, and these patients were excluded from 
further analysis. If hydroimidazolone is causally involved in early nephropathy is not known. 
In the present study, no association was shown between hydroimidazolone and urinary 
albumin-creatinine ratio.  
We measured hemoglobin, albumin and VEGF, adapting the methods for vitreous. This 
enabled a more extensive discussion and thorough interpretation of the true vitreous content 
of hydroimidazolone in Paper 2. Intravitreal measurements of albumin used as an indirect sign 
of iBRB disruption are seldseen. In our study, the correlation of vitreous albumin and 
hydroimidazolone is explained by the increase of vitreous albumin in the PDR group, due to a 
breakdown of the iBRB. Hydroimidazolone most likely originated from serum, whereas 
VEGF was produced intraocularly. No correlation between vitreous hydroimidazolone and 
VEGF was found in our study. However, the number of subjects studied was small.  
In Paper 4, we found a low cumulative incidence of PDR after 24 years of type1 diabetes. The 
study had a population based design, but there was a marked proportion of non-participants 
and losses for follow-up. Thus, a sensitivity analysis was done to assess any influence of 
selection bias on risk for retinopathy. As regards PDR, a higher cumulative incidence of 
14.0% was found with this method (versus 10.9%). Still, this is relatively low. However, the 
proportion of subjects with NPDR was substantial (78.6%). There remains a potential for still 
improved glycemic control and optimization of other risk factors that can be modified, like 
blood pressure and triglycerides. A uniform screening system is still missing in Norway, as 
are registers for incident blindness. This study is a contribution to increased knowledge on 
microvascular complications nationwide, and as such a stimulus for further research and 
improvement of prophylactic measures.      
 
10. Concluding remarks (Relevance of papers, future research) 
The exact pathogenic mechanisms of diabetic retinopathy are only partly revealed. Interplay 
of ROS and AGEs are plausible. Most probably, the explanation consists of multiple factors. 
The range of functionally and structurally different AGEs also makes it difficult to point out 
which AGE is the most pathogenic.  
Exogenous AGEs (from coffee, smoking, foods etc) and their disputed pathogenic role are not 
discussed in this paper. In general, a limited consumption is recommended due to their 
abundance in “unhealthy food”, but in particular if reduced kidney function exists (143) (144).  
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Elegant approaches for potential interventions in restricting the burden of endogenous AGEs 
have emerged, attacking at the following sites: 
a) AGE formation may be inhibited by trapping of reactive (di)carbonyls in the glycation process 
and chelation of transition metal ions (e.g. by aminoguanidine, pyridoxamine). Unfortunately, 
aminoguanidine has toxic side effects which has lead to discontinuation of clinical studies 
(145) (146). A drug category already in use – inhibiting the angiotensin-converting enzyme – 
has anti-hypertensive effect but is also potent as AGE inhibitor (147). 
b) AGE cross-links may be broken down. PTB (N-phenacylthiazolium bromide) and ALT-711 
(alagebrium chloride), cleave AGE-mediated cross-links (89). 
c) AGE binding may be inhibited. The binding of ligand to AGE receptor include soluble RAGE 
(sRAGE) and RAGE specific antibodies, neutralizing the effect of receptor interaction (148) 
(149). 
d) ROS/AGE interaction may be targeted via antioxidants, exemplified by improved retinal blood 
flow in type 1 diabetics after high-dose vitamin E supplementation (150).  
Productive “anti-AGEs” research makes future important clinical implications of this 
knowledge probable, including retinopathy.  
 
Our findings strongly support the following statements: 
 
 Serum levels of the AGE-modification hydroimidazolone (MG-H1) are increased in both type 
1 and type 2 diabetic patients with retinopathy compared to those without retinopathy. 
 Serum levels of hydroimidazolone (MG-H1) are increased in PDR compared to NPDR 
(diabetes mellitus type 2). 
  Vitreous levels of hydroimidazolone (MG-H1) are increased in type 2-diabetic patients 
compared to age-matched controls due to leakage from serum. 
 Vitreous levels of hydroimidazolone (MG-H1) are increased in PDR compared to NPDR in 
type 2-diabetic patients, and may originate from serum due to iBRB breakdown.  
 VEGF in vitreous fluid is increased in diabetes type 2. Even higher levels are found in PDR. 
The increase in VEGF is not due to a spill-over effect from the circulation, even though the 
iBRB is disrupted, supporting that it is produced intraocularly. 
Patients with type 1 diabetes of 24 years duration and retinopathy staged from fundus 
photographs had 89.1% cumulative incidence for DR. 10.5% of these have PDR.   
 
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